Supplemental Table S1. Pragmatic characteristics of trial elements in the Co-Work-Care trial

(from https://rethinkingclinicaltrials.org/chapters/pragmatic-clinical-trial/pragmatic-elements-an-introduction-to-precis-2/)

<table>
<thead>
<tr>
<th>Trial element</th>
<th>Pragmatic characteristics in Co-Work Care trial</th>
</tr>
</thead>
<tbody>
<tr>
<td>Research question</td>
<td>Whether enhanced and early cooperation plus early person centered dialogue is more effective in reducing total duration of sick-leave for primary care patients with reduced function because of CMD</td>
</tr>
<tr>
<td>Setting</td>
<td>Embedded in the routine primary care setting</td>
</tr>
<tr>
<td>Participants</td>
<td>Primary care patients with reduced function because of CMD</td>
</tr>
<tr>
<td>Intervention and comparator</td>
<td>Compares two real-world treatments using flexible protocols – care manager contact plus enhanced and early cooperation and early person centered dialogue vs care manager contact as usual</td>
</tr>
<tr>
<td>Outcomes</td>
<td>Endpoints clinically relevant to participants, funders, communities, and healthcare providers</td>
</tr>
<tr>
<td>Clinical importance</td>
<td>Purposely designed for making healthcare decisions in settings in which the intervention will be implemented and be used. Important clinical questions can be answered directly from trial results</td>
</tr>
</tbody>
</table>
Supplemental Figure S1. Survival pattern of cumulative return to work (full or part time sick-leave to no sick-leave), gross number of days on sick-leave 12 months. Cox regression analysis controlled for age, gender and education. No significant difference between intervention (blue) and control (green) group RTW (hazard ratio=0.881, 95% CI 0.688 to 1.128).
Supplemental Figure S2 (below). Course of MADRS-S (a), GAD-7(b), KEDS (c), WAI (d), and EQ-5D (e) from baseline to 12 months follow up (adjusted means). Mixed model analysis, adjusted for clustering, age, sex, education, antidepressants at inclusion.
Adjusted mean KEDS

S2 c)
Adjusted mean WAI(1-10p)

S2 d)

0 month 3 month 6 month 12 month

- Intervention
- Control
Adjusted mean EQ5D(1-100p)

0 month | 3 month | 6 month | 12 month

Intervention | Control

Supplemental Figure S3 (below). Course of MADRS-S, GAD-7, KEDS for patients with moderate/high levels (n= 284) from baseline to 12 months follow up (adjusted means). Mixed model analysis, adjusted for clustering, age, sex, education, and antidepressants at inclusion.

1) All patients with MADRS-S ≥ 20: significant difference at 12 months;
2) All patients with GAD≥10: significant difference at 12 months;
3) All patients with KEDS≥ 30: no significant differences.
S3 1) Adjusted mean MADRS-S

- Intervention MADRS \( \geq 20 \)
- Control MADRS \( \geq 20 \)
S3 2)

Adjusted mean GAD-7

- Intervention GAD7 ≥ 10
- Control GAD7 ≥ 10

0 month 3 month 6 month 12 month
S3 3) Adjusted mean KEDS

- Intervention KEDST ≥ 30
- Control KEDS ≥ 30